Jun 21, 2022· Comment from Association for Accessible Medicines (AAM)· FDA-2022-N-0165-0157
FDA, The Association for Accessible Medicines (AAM) appreciates the opportunity to submit comments on the draft guidance, "Providing Mail-Back Envelopes and Education on Safe Disposal With Opioid Analgesics Dispensed in an Outpatient Setting" (Docket No. FDA-2022-N-0165). Please find attached AAM's comments on this draft guidance. Thanks, Scott Kuzner, Ph.D. Senior Director, Sciences and Regulatory Affairs Association for Accessible Medicines (AAM)